Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A novel lncRNA MTAR1 promotes cancer development through IGF2BPs mediated post-transcriptional regulation of c-MYC


Abnormal translation of the MYC proto-oncogene is a hallmark of the initiation and maintenance of tumorigenesis. However, the molecular mechanism underlying increased MYC protein levels in certain cancer types without a corresponding increase in MYC mRNA levels is unclear. Here, we identified a novel lncRNA, MTAR1, which is critical for post-transcriptional regulation of MYC-induced tumorigenesis. MTAR1 is essential for recruiting IGF2BPs into PABP1-mediated liquid–liquid phase separation (LLPS) complexes and facilitates IGF2BPs-mediated MYC mRNA translation. MTAR1 enhanced binding between IGF2BPs and PABP1, thereby promoting MYC mRNA stability and increased MYC mRNA translation. In summary, MTAR1 is a novel MYC-related lncRNA that contributes to tumor progression by enhancing MYC translation through mediating PABP1/IGF2BPs liquid–liquid phase separation.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: TCONS_02256997 expression is highly correlated with c-MYC translation.
Fig. 2: MTAR1 is an oncogenic lncRNA and may affect human cancer cell phenotype through the MYC pathway.
Fig. 3: MTAR1 is an oncogenic lncRNA associated with tumorigenesis.
Fig. 4: MTAR1 interacts with protein IGF2BPs and PABP1 that may positively regulate MYC translation.
Fig. 5: PABP1 can facilitate LLPS and complex with IGF2BP.
Fig. 6: MTAR1 reinforces the interaction between PABP1 and IGF2BP2, thus promotes MYC translation.


  1. Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.

    Article  CAS  Google Scholar 

  2. Eilers M, Eisenman RN. Myc’s broad reach. Genes Dev. 2008;22:2755–66.

    Article  CAS  Google Scholar 

  3. Chang T-C, Yu D, Lee Y-S, Wentzel EA, Arking DE, West KM, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40:43–50.

    Article  CAS  Google Scholar 

  4. Bachireddy P, Rakhra K, Felsher D. Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clin Exp Immunol. 2012;167:188–94.

    Article  CAS  Google Scholar 

  5. Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014;4:a014241.

    Article  Google Scholar 

  6. Wang J, Liu Z, Wang Z, Wang S, Chen Z, Li Z, et al. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. Cancer Lett. 2018;419:64–74.

    Article  CAS  Google Scholar 

  7. Lian Y, Niu X, Cai H, Yang X, Ma H, Ma S, et al. Clinicopathological significance of c-MYC in esophageal squamous cell carcinoma. Tumor Biol. 2017;39:1010428317715804.

    Article  Google Scholar 

  8. Hunecke D, Spanel R, Länger F, Nam SW, Borlak J. MYC‐regulated genes involved in liver cell dysplasia identified in a transgenic model of liver cancer. J Pathol. 2012;228:520–33.

    Article  CAS  Google Scholar 

  9. Borzi C, Calzolari L, Ferretti AM, Caleca L, Pastorino U, Sozzi G, et al. c-Myc shuttled by tumour-derived extracellular vesicles promotes lung bronchial cell proliferation through miR-19b and miR-92a. Cell Death Dis. 2019;10:1–16.

    Article  CAS  Google Scholar 

  10. Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N 6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat cell Biol. 2018;20:285–95.

    Article  CAS  Google Scholar 

  11. Marderosian M, Sharma A, Funk A, Vartanian R, Masri J, Jo O, et al. Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene. 2006;25:6277–90.

    Article  CAS  Google Scholar 

  12. Zhang K, Pomyen Y, Barry AE, Martin SP, Khatib S, Knight L, et al. AGO2 mediates MYC mRNA stability in hepatocellular carcinoma. Mol Cancer Res. 2020;18:612–22.

    Article  CAS  Google Scholar 

  13. Christoffersen N, Shalgi R, Frankel L, Leucci E, Lees M, Klausen M, et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 2010;17:236–45.

    Article  CAS  Google Scholar 

  14. Liu Z, Zhang G, Li J, Liu J, Lv P. The tumor-suppressive microRNA-135b targets c-myc in osteoscarcoma. PloS One. 2014;9:e102621.

    Article  Google Scholar 

  15. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007;67:9762–70.

    Article  CAS  Google Scholar 

  16. Ernst C, Morton C. Identification and function of long non-coding RNA. Front Cell Neurosci. (Review) 2013;7:168.

  17. Guo C-J, Ma X-K, Xing Y-H, Zheng C-C, Xu Y-F, Shan L, et al. Distinct processing of lncRNAs contributes to non-conserved functions in stem cells. Cell. 2020;181:621–636.e622

    Article  CAS  Google Scholar 

  18. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393–407.

    Article  CAS  Google Scholar 

  19. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–81.

    Article  CAS  Google Scholar 

  20. Yao R-W, Wang Y, Chen L-L. Cellular functions of long noncoding RNAs. Nat Cell Biol. 2019;21:542–51.

    Article  CAS  Google Scholar 

  21. Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021;220:e202009045.

    Article  CAS  Google Scholar 

  22. Tsang B, Pritišanac I, Scherer SW, Moses AM, Forman-Kay JD. Phase separation as a missing mechanism for interpretation of disease mutations. Cell. 2020;183:1742–56.

    Article  CAS  Google Scholar 

  23. Aguzzi A, Altmeyer M. Phase separation: linking cellular compartmentalization to disease. Trends Cell Biol. 2016;26:547–58.

    Article  CAS  Google Scholar 

  24. Cai D, Feliciano D, Dong P, Flores E, Gruebele M, Porat-Shliom N, et al. Phase separation of YAP reorganizes genome topology for long-term YAP target gene expression. Nat Cell Biol. 2019;21:1578–89.

    Article  CAS  Google Scholar 

  25. Sabari BR, Dall’Agnese A, Boija A, Klein IA, Coffey EL, Shrinivas K, et al. Coactivator condensation at super-enhancers links phase separation and gene control. Science. 2018;361:3958.

  26. Esposito M, Fang C, Cook KC, Park N, Wei Y, Spadazzi C, et al. TGF-β-induced DACT1 biomolecular condensates repress Wnt signalling to promote bone metastasis. Nat Cell Biol. 2021;23:257–267.

  27. Zhou W, Mohr L, Maciejowski J, Kranzusch PJ. cGAS phase separation inhibits TREX1-mediated DNA degradation and enhances cytosolic DNA sensing. Mol Cell. 2021;81:739–55.e737

    Article  CAS  Google Scholar 

  28. Sauvageau M. Diverging RNPs: toward understanding lncRNA-protein interactions and functions. Biol mRNA: Struct Funct. 2019:1203:285–312.

  29. Cao J, Mu Q, Huang H. The roles of insulin-like growth factor 2 mRNA-binding protein 2 in cancer and cancer stem cells. Stem Cells Int. 2018;2018:4217259.

  30. Bell JL, Wächter K, Mühleck B, Pazaitis N, Köhn M, Lederer M, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci. 2013;70:2657–75.

    Article  CAS  Google Scholar 

  31. Patel GP, Ma S, Bag J. The autoregulatory translational control element of poly (A)-binding protein mRNA forms a heteromeric ribonucleoprotein complex. Nucleic Acids Res. 2005;33:7074–89.

    Article  CAS  Google Scholar 

  32. Hyman AA, Weber CA, Jülicher F. Liquid-liquid phase separation in biology. Annu Rev Cell Dev Biol. 2014;30:39–58.

    CAS  PubMed  Google Scholar 

  33. Lu Y, Wu T, Gutman O, Lu H, Zhou Q, Henis YI, et al. Phase separation of TAZ compartmentalizes the transcription machinery to promote gene expression. Nat Cell Biol. 2020;22:453–64.

    Article  CAS  Google Scholar 

  34. Zhou H-X, Nguemaha V, Mazarakos K, Qin S. Why do disordered and structured proteins behave differently in phase separation? Trends Biochem Sci. 2018;43:499–516.

    Article  CAS  Google Scholar 

  35. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18:3004–16.

    Article  CAS  Google Scholar 

  36. Zimmerman K, Alt F. Expression and function of myc family genes. Crit Rev Oncog. 1990;2:75–95.

    CAS  PubMed  Google Scholar 

  37. Meichle A, Philipp A, Eilers M. The functions of Myc proteins. Biochim Biophys Acta (BBA)-Rev Cancer. 1992;1114:129–46.

    Article  CAS  Google Scholar 

  38. Casey SC, Baylot V, Felsher DW. The MYC oncogene is a global regulator of the immune response. Blood. 2018;131:2007–15.

    Article  CAS  Google Scholar 

  39. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: marvelously complex. Adv Cancer Res. 2002;84:81–154.

  40. Bolha L, Ravnik-Glavač M, Glavač D. Long noncoding RNAs as biomarkers in cancer. Dis Markers. 2017; 2017.

  41. Yu Y, Zhang W, Li A, Chen Y, Ou Q, He Z, et al. Association of long noncoding rna biomarkers with clinical immune subtype and prediction of immunotherapy response in patients with cancer. JAMA Netw Open. 2020;3:e202149–e202149.

    Article  Google Scholar 

  42. Brangwynne C. Germline P granules are liquid droplets that localize by controlled dissolution/condensation. Science. 2009;324:1729–32.

    Article  CAS  Google Scholar 

  43. Zaslavsky BY, Ferreira LA, Uversky VN. Driving forces of liquid–liquid phase separation in biological systems. Biomolecules. 2019;9:473.

  44. Zhang H, Ji X, Li P, Liu C, Lou J, Wang Z, et al. Liquid-liquid phase separation in biology: mechanisms, physiological functions and human diseases. Sci China Life Sci. 2020;63:953–85.

    Article  Google Scholar 

  45. Fox AH, Nakagawa S, Hirose T, Bond CS. Paraspeckles: where long noncoding RNA meets phase separation. Trends Biochem Sci. 2018;43:124–35.

    Article  CAS  Google Scholar 

  46. Labun K, Montague TG, Krause M, Cleuren YT, Tieldnes H, Valen E. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. Nucleic Acids Res. 2019;47:171–4.

    Article  Google Scholar 

Download references


We thank Dr. Kyle Vaughn Laster for editing this manuscript. We thank Liwen Bianji, Edanz Editing China ( and professor Andrew Dingley, for editing this manuscript. We thank for their software that enabled us to generate the graphic abstract.


This research is supported by the National Natural Science Foundations of China (No. 81802876), the Project of Science and Technology of the Henan Province for Tackling Key Problems (182102310128) and the National Natural Science Foundations of China (Nos. 81872335, 81802875, 81972639).

Author information

Authors and Affiliations



YFG, first author, main implementer, took participate into all parts of work of this manuscript. MJ, co-first author, main implementer, took most part of work of this manuscript. FQG, participated in designing and performing in vitro experiments. XJL, took part in performing cell culture experiments and formal analysis. QZ, participated in most in vitro experiments. SY, took all microscopy pictures and 3D model. YTY, participated in developing and designing the RNA assay. RY, made all of the pathological paraffin slices. KKW, gene sequencing data analysis. QW, established CDX and PDX mice models. DDZ, participated in part of in vivo experiments. CJZ, collaborator from Henan Cancer hospital and provided ESCC tumor samples. KVL, manuscript revising and editing. MMG, took part in some cell culture experiments. WNN, protein MS analysis. KDL, co-corresponding author, project administration, management and coordination responsibility for the research activity planning and execution. ZGD, corresponding author, project supervision, oversight and leadership responsibility for the research activity planning and execution, including mentorship external to the core team.

Corresponding authors

Correspondence to Kangdong Liu or Zigang Dong.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Tumor and adjacent ESCC tissues were obtained from ESCC cancer patients who underwent surgery at Henan Cancer Hospital. The experimental protocol was approved by the ethics committee of Zhengzhou University School of Medicine, Henan Cancer Hospital (No. 2017407). No patient received chemotherapy or radiotherapy prior to surgery. Animal experimental protocol was approved by the ethics committee of China-US (Henan) Hormel Cancer Institute (No. CUHCI2019003).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gao, Y., Jiang, M., Guo, F. et al. A novel lncRNA MTAR1 promotes cancer development through IGF2BPs mediated post-transcriptional regulation of c-MYC. Oncogene 41, 4736–4753 (2022).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links